STOCK TITAN

Pharvaris officer may sell 46,400 shares in 2026

An officer of Pharvaris N.V. has filed to potentially sell 46,400 common shares under Rule 144, mainly from option exercise and restricted stock.

(Neutral)
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Pharvaris N.V. (PHVS) is named as the issuer in a notice that Stefan Andreas Abele, an officer, may sell up to 46,400 common shares under Rule 144 through Morgan Stanley Smith Barney LLC on or after September 15, 2026 on NASDAQ. The shares include 45,000 shares from a stock option exercise dated September 15, 2026 and a total of 1,400 restricted stock shares from grants dated June 8, 9, 11, 12, 2026 and August 11, 2026.

Positive

  • None.

Negative

  • None.
Common shares to be sold under Rule 144 46,400 shares Maximum Pharvaris N.V. common shares indicated for sale
Aggregate market value of shares $1,771,125.04 Value associated with 46,400 common shares
Shares from stock option exercise 45,000 shares Common shares underlying stock option exercise dated September 15, 2026
Restricted stock shares 1,400 shares 274, 418, 548, 18, and 142 shares from grants in June and August 2026
Proposed sale date September 15, 2026 Date associated with the planned sale of 46,400 common shares
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Stock Option Exercise financial
"Common | 09/15/2026 | Stock Option Exercise | Issuer"
A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.
Restricted Stock financial
"Common | 06/11/2026 | Restricted Stock | Issuer"
Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for Pharvaris N.V. (PHVS)?

It discloses that officer Stefan Andreas Abele may sell up to 46,400 common shares of Pharvaris N.V. under Rule 144 through Morgan Stanley Smith Barney LLC, with sales indicated as of September 15, 2026 on NASDAQ.

How many Pharvaris (PHVS) shares are planned to be sold and of what type?

The filing indicates up to 46,400 common shares, consisting of 45,000 shares from a stock option exercise dated September 15, 2026 and 1,400 restricted stock shares from several grant dates in June and August 2026.

What is the reported aggregate market value of the Pharvaris (PHVS) shares in the Form 144?

The Form 144 lists an aggregate market value of $1,771,125.04 for the 46,400 Pharvaris common shares that may be sold under Rule 144 as of the indicated date of September 15, 2026.

Which broker is named for the potential sale of Pharvaris (PHVS) shares?

The potential sale is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004, as listed for the common shares to be sold under Rule 144.

What equity awards underlie the Pharvaris (PHVS) shares to be sold?

The shares include 45,000 common shares from a stock option exercise dated September 15, 2026 and restricted stock grants of 274, 418, 548, 18, and 142 shares from dates in June and August 2026, totaling 1,400 restricted shares.

On which market are the Pharvaris (PHVS) shares indicated to be sold?

The common shares covered by the notice are indicated for potential sale on NASDAQ as of September 15, 2026, with up to 46,400 shares of Pharvaris N.V. common stock listed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Keep reading